Avacta Group plc, a UK-based healthcare technology and consumables business, provides innovative and proprietary solutions to the life sciences/healthcare sector through two operating divisions:

Avacta Analytical provides high-end analytical instrumentation and services to the biopharmaceutical sector, expected to be a US$200bn revenue market by 2013 and the fastest growing part of the pharmaceutical industry. The Company’s technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Company’s lead analytical instrument, Optim, is distributed through Pall Corporation in US and SE Asia, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.

Avacta Animal Health provides diagnostic products and services for the US$1.5bn global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information through point of care diagnostics and laboratory based testing. Avacta’s AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta’s world leading allergy testing brand Sensitest®. Avacta is developing further assays for the AX-1 system to diagnose a range of diseases in companion animals. Longer term, these technologies will be transferred into the human clinical diagnostics market.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

http://www.avacta.com/

Nice one DC

Again a big swing to buys, should bode well for the near future.

Strong purchasing.

If this buying pace keeps up, this one should come right.

On the move now

Up 7%

I have great hopes for this stock,,,,,,,,the sector is hot at the moment IMO

Strong buying after some profit taking this morning

You will alway's get the profit takers that are happy with their 20%,,,,I'm hanging around for a far bigger chunk from AVCT,,,,,,,,,all IMO

After a couple of weeks of selling, good to see a swing round to buying.

The buying is picking up.

Kept hold of these ? In SM today - Healthcare Technology company Avacta is likely to experience a sales upturn now the latest model of its protein analyser , Optim 2 , is on the shelves. Panmure Gordon has set a 1.75p target.

Interim Results

RNS


RNS Number : 5297D

Avacta Group PLC

30 April 2013








30 April 2013


Avacta Group plc

("Avacta" or the "Group")

Interim Results

Avacta Group plc, a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, is pleased to announce its interim results for the period ended 31 January 2013.



Highlights


·

Revenue of £1.15 million (2012: £1.72 million) slowed by the transition to the next generation Optim2 product and movements in the US distributor channel


·

Operating loss of £0.97 million (2012: £0.52 million)


·

Loss per share increased to 0.03 pence (2012: 0.02 pence)


·

Optim2 launched globally on 1 February 2013


·

Optim2 distributor transition to ForteBio complete


·

Optim2 order intake since 1 February 2013 of 10 units with over 125 validated prospects in the pipeline


·

Optim consumable cartridge revenue increased 94% year on year to £136,000


·

AX-1 Sensipod field trial with vets concluded and release model of Sensipod now in production


·

Sensipod test menu expanding as commercial launch approaches: several further tests well advanced with commercial availability anticipated shortly after Sensipod launch


·

Affimer reagents development in line with management expectation and first commercial launch planned during 2014

- high throughput Affimer production facility to supply microarray printing established, commissioned and generating Affimers

- library screening facilities operational and being commissioned

- in-house microarray prototyping being optimised and outsource array manufacturing partner selected

- early stage commercial interest in Affimer reagents as antibody replacements strong



Alastair Smith, Chief Executive Officer, commented:

"As we forecast in our Business Update in February 2013 and Preliminary Results in October 2012, revenues for this period are below last year because Optim sales temporarily slowed as we introduced our next generation, upgraded Optim2 device, and trained up the sales team at ForteBio, the newly acquired subsidiary of our partner Pall Corporation.



"We believe this short-term slow down will be justified long-term as ForteBio, which has a specialist high-end instrument sales team, is now fully trained. Indeed, we have already seen 10 orders for Optim2 since 1 February 2013 and a strong pipeline of prospective orders.



"Further progress has come through our Animal Health division, which has completed field trials of the AX-1 Sensipod, our point-of-care diagnostic system for veterinary clinics. This has allowed us to capture several minor, but nevertheless important improvements that will enhance the user experience. These changes are now incorporated and production of the commercial units is underway. In the period we also advanced the development of further tests for the Sensipod, which gives us confidence that the test menu will grow soon after the commercial launch of the product.



"Finally, we are very excited about the Affimer reagents platform. We have received a lot of interest in Affimers as affinity reagents to replace or compliment antibodies, and also in the Affimer microarrays for drug and biomarker discovery that we have proposed. There has been good progress in setting up the Affimer screening and production facilities which are functional and being optimised and we remain confident of first revenues from Affimers in 2014.



"Over the coming period we anticipate further progress on all fronts and look forward to reporting on this in due course, particularly on first sales of the AX-1 Sensipod product."





- Ends -

Avacta Group: Numis initiates with a target price of 1.70p and a buy recommendation

Conditional Placing to Raise ?4.7 Million

RNS


RNS Number : 5813J

Avacta Group PLC

18 July 2013






THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION IS PROHIBITED.








Press Release

18 July 2013




Avacta Group plc

("Avacta" or the "Group")



Conditional Placing to Raise £4.7 Million





Avacta Group plc (LSE: AVCT) a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, announces today that it has raised, subject to certain conditions, £4.7 million (before expenses) by way of a placing of 854,545,457 new Ordinary Shares (the "Placing Shares") with both new and existing institutional shareholders at a price of 0.55 pence per Ordinary Share.



The net proceeds of the issue of the Placing Shares of approximately £4.5 million, will be used to accelerate the Group's development and commercialisation of Affimers, to support the early stage commercialisation of the Sensipod in-clinic analyser in the veterinary market and to continue the development of the Optim instrument.



Alastair Smith, Chief Executive of Avacta, commented: "We are delighted to have successfully raised these funds through both existing and new shareholders. The Board looks forward to utilising the proceeds of the Placing to build the Life Sciences division of our business, specifically developing the Affimer platform. Although currently at an early stage, the Board sees this as being a key division contributing to revenue growth in our business in future and it is vital that the commercialisation plan is executed effectively. We will also shortly be undertaking commercial roll out of the Sensipod diagnostics system following recent successful field trials.



"It is pleasing that the Placing Price is at a small premium to the middle market share price of 0.535 pence per Ordinary Share on 17 July 2013, and that there was greater demand than the final placing amount."



The Placing Shares will, upon Admission, rank pari passu in all respects with the Ordinary Shares in issue as at that date, including as regards the right to receive all dividends or other distributions declared, made or paid after Admission. The Placing Shares will represent approximately 21.3 per cent. of the Company's enlarged issued ordinary share capital immediately following completion of the Placing.



A general meeting of Avacta in connection with, amongst other things, the Placing will be held at 10.00am on 5 August 2013 at the offices of Walker Morris LLP at Kings Court, 12 King Street, Leeds LS1 2HL.



Further details of the Placing are below.

up 29% on the day.

Avacta Group: Numis shifts target price from 1.70p to 1.40p keeping its buy recommendation.

Started watching this one at 1.3p Did some research and watched it drop and now back up to 0.93.

a couple of positive news articles and the launch of it's testing kit to vets.

The real money in this is not the testing kits but the consumables.

The sells shown today are most likely buys as I am got brought in and mine was shown as a sell.

Started watching this one at 1.3p Did some research and watched it drop and now back up to 0.93.

a couple of positive news articles and the launch of it's testing kit to vets.

The real money in this is not the testing kits but the consumables.

The sells shown today are most likely buys, I just brought in and mine was shown as a sell.

from the 16th Sep
Shares in Avacta (AVCT) are up 11% today 0.91p but the hot money is heading in and reckons that the shares could be heading for 2p before too long.

The reason for today’s rise is that the provider of diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare appointed Dr Matt Johnson to lead the Group's Affimer technology development and production teams. Dr Johnson joins Avacta from Abcam plc where he was Head of R&D.

That is the key. Abcam delivered pretty cracking gains for a range of fund managers over the past few years and they all know Dr Johnson well. Expect more sustained buying from those in the know who reckon that, from here, Avacta shares could easily double.
- See more at: http://www.shareprophets.com/views/1611/hot-money-buys-avacta-at-091p-reckons-2p-on-the-cards#sthash.smUhw6mR.dpuf